Stock Track | Jazz Pharmaceuticals Soars 5.02% in Post-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance

Stock Track

May 06

Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.02% in post-market trading on Tuesday.

The surge follows the company's release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, beating the consensus estimate of $4.57, while revenue rose 19% year-over-year to $1.07 billion, also above forecasts. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.

Additionally, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. These positive results and sustained outlook likely fueled investor optimism, leading to the sharp post-market gain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1178501319"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178501319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178501319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 08:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178501319","market":"sg","top_or_hot":-1,"title":"Stock Track | Jazz Pharmaceuticals Soars 5.02% in Post-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance","media":"Stock Track","content":"<p>Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.02% in post-market trading on Tuesday.</p><p>The surge follows the company's release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, beating the consensus estimate of $4.57, while revenue rose 19% year-over-year to $1.07 billion, also above forecasts. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.</p><p>Additionally, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. These positive results and sustained outlook likely fueled investor optimism, leading to the sharp post-market gain.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Jazz Pharmaceuticals Soars 5.02% in Post-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Jazz Pharmaceuticals Soars 5.02% in Post-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 08:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.02% in post-market trading on Tuesday.</p><p>The surge follows the company's release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, beating the consensus estimate of $4.57, while revenue rose 19% year-over-year to $1.07 billion, also above forecasts. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.</p><p>Additionally, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. These positive results and sustained outlook likely fueled investor optimism, leading to the sharp post-market gain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"","article_id":"1178501319","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178501319","pubTimestamp":1778027231,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.02% in post-market trading on Tuesday.The surge follows the company's release of its first-quarter 2026 financial results, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"个股追踪|Jazz Pharmaceuticals盘后飙升5.02%，因Q1盈利强劲超出预期并重申指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.02% in post-market trading on Tuesday.The surge follows the company's release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, beating the consensus estimate of $4.57, while revenue rose 19% year-over-year to $1.07 billion, also above forecasts. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.Additionally, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. These positive results and sustained outlook likely fueled investor optimism, leading to the sharp post-market gain.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}